You are here: Home » Companies » News
Business Standard

Nektar's R&D facility to come up in Hyd

BS Reporter  |  Chennai/ Hyderabad 

This is company's first R&D facility outside the US.
Nektar Therapeutics, a biopharmaceutical company, is setting up its first research and development centre outside the US at the ICICI Knowledge Park on the outskirts of Hyderabad.
Spread over an extent of 15 acres, the facility would have a built-up area of up to 40,000 square feet. It will have a headcount of 80 to 100 people to start with. Over the last two years, Nektar has been operating here with about 40 employees from a leased facility.
"The Hyderabad facility significantly accelerates Nektar's global R&D," company's president and chief executive officer, Howard Robin, told mediapersons.
He, however, expressed his inability to disclose the quantum of investment being made in the new facility, the foundation stone for which was laid by Andhra Pradesh chief minister, YS Rajasekhara Reddy, on Friday.
Robin said that Nektar's decision to come to India was largely based on the availability of "outstanding number of educated scientists," who could provide R&D output faster, and at a lower cost.
According to Robin, Nektar's pulmonary and PEGylation technology and manufacturing capabilities have enabled nine approved products for partners, which include world's leading pharmaceutical and biotechnology like Pfizer, Novartis and Bayer.
The company has also developed its own products by applying the same technology to existing medicines with the objective of improving efficacy, safety and compliance.
Explaining that Nectar is the world leader in PEGylation technology, he said that every single PEGylated product approved over the last 10 years had been enabled by the company.
PEGylation is adding various structures to molecules to improve efficacy of medicines.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, May 07 2007. 00:00 IST